Protection against the respiratory syncytial virus (RSV) must expand to lower-income countries, which are harder hit.Credit: Hailshadow/Getty.
“Something’s wrong with the data. There are too few people in hospitals” with respiratory syncytial virus (RSV), epidemiologist Caroline Klint Johannesen recalls a colleague remarking while analysing Danish health records for last winter.
On 1 October 2025, Denmark introduced a nationwide policy of vaccinating pregnant people against RSV — a respiratory pathogen that usually causes mild symptoms but can lead to severe disease and even death in vulnerable people, including infants and older adults. Maternal antibodies induced by the vaccine cross the placenta to protect babies for around the first six months of their lives, when they are most at risk. Newborns at high risk of severe disease, including premature infants, whose mothers had not been vaccinated, were given injections of monoclonal antibodies.
RSV wave hammers hospitals — but vaccines and treatments are coming.
RSV wave hammers hospitals — but vaccines and treatments are coming.
Johannesen, a vaccine researcher at Nordsjællands Hospital in Hillerød, Denmark, found1 that infant hospital admissions plummeted. The immunizations are working, she says (see ‘Newborn protection’).
According to recent reports, the World Health Organization (WHO) estimates that every year, RSV hospitalizes roughly 3.6 million and kills about 100,000 children under 5 years old. Of these deaths, 97% occur in low- and middle-income countries (LMICs).
The virus is also dangerous to older adults — although those risks are widely underappreciated by both physicians and the public. Historically, testing has been sparse, and there are no global statistics for RSV-related adult deaths. But over the age of 60, hospitalizations and mortality increase with age, especially in people with other diseases such as chronic heart and lung conditions. In the United States, the Centers for Disease Control and Prevention (CDC) estimates that between around 10,000 and 25,000 people have died in each of the past two winters, especially in older age groups.
Since 2022, when European regulators approved nirsevimab — a long-acting monoclonal antibody against RSV — a second antibody and three vaccines have been developed for use in adults, one of which is suitable for pregnant people.
According to recent reports, “It’s just remarkable,” states Buddy Creech, a paediatrician at Vanderbilt University in Nashville, Tennessee, to have gone “from no mechanism to prevent RSV to an embarrassment of riches”. Dozens of countries across Europe, Asia and North and South America have debuted various immunization programmes.
doi: https://doi.org/10.1038/d41586-026-03573-3.
In a recent development, correction 13 November 2026: An earlier version of this article mentioned that vaccines were offered only to 75–79-year-olds in Scotland in 2024–25. This has been updated to 74–79-year-olds because people who would turn 75 by July 2025 were included.
It has been revealed that klint Johannesen, C., Egeskov-Cavling, A. M., Lund, S., Barrella Harboe, Z. & Fischer, T. K. Lancet Reg. Health Eur. 66, 101750 (2026).
Article PubMed Google Scholar.
Trusinska, D. et al. Lancet Reg. Health Eur. 64, 101623 (2026).
Article PubMed Google Scholar.
Hameed, S. S. et al. Lancet Infect. Dis. 25, 256–258 (2025).
Article PubMed Google Scholar.
Razzini, J. L. et al. Lancet Reg. Health Am. 52, 101296 (2025).
PubMed Google Scholar.
Sources indicate that torres, J. P. et al. Lancet Infect. Dis. 25, 1189–1198 (2025).
Article PubMed Google Scholar.
Will a new wave of RSV vaccines stop the dangerous virus?
RSV treatments are here: now the work begins.
First vaccine to protect babies from life-threatening respiratory syncytial virus (RSV).
RSV poses serious risks, but upcoming vaccine options are emerging.
Vaccines could offer fresh hope against respiratory syncytial virus.
RSV wave hammers hospitals — but vaccines and treatments are coming.
Chinese scientist sacked after child died in gene-editing trial.
New CRISPR therapy is poised to gain first FDA approval to alter genes inside the body.
Move over BMI: new obesity definition is better for predicting your health.
Measles made a stealthy return as another virus took the spotlight.
Dengue comes back even in vaccinated people — fresh clues.
Moderna mRNA vaccine almost halves the risk of skin cancer returning.
Move over BMI: upcoming obesity definition is better for predicting your health.
The super El Niño is more than a climate shock – it’s a health one, too.
Mysterious anthrax outbreak kills hippos in Africa — raising concerns for human spread.
Recent findings suggest that NBIC, Peking University, seeks Assistant Professors and Research Track faculty in imaging, probes, spatial omics and digital life. Open until filled.
National Biomedical Imaging Center, College of Future Technology, Peking University.
Job Title: Deputy Editor, Nature Progress Bioengineering Location: Shanghai, Beijing, Upcoming York, Philadelphia - hybrid working model Closing date: 2...
Shanghai, Beijing, Latest York, Philadelphia - hybrid working model.
The SoQ invites highly qualified faculty member in quantum sciences & technology and related fields.
School of Quantum at the University of Chinese Academy of Sciences (UCAS).
Join HZAU's global faculty team to advance research with competitive benefits.
Huazhong Agricultural University (HZAU).
The School of Life Science and Technology (SLST) invites applications for numerous tenure-track and tenured positions.
